

Clinuvel granted US topical formulation patent

Protection granted for novel formulations of new class of melanin activating drugs

Baar, Switzerland and Melbourne, Australia November 8 2011

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that the United States Patent and Trademark Office (USPTO) has granted Clinuvel pivotal patent protection for the delivery of melanocortins as photoprotective agents in transdermal formulations. Clinuvel has two melanocortin drugs in development (afamelanotide and CUV9900), both of which are analogues of the naturally occurring hormone alpha-Melanocyte Stimulating Hormone (alpha-MSH).

Patent 20110263508 grants Clinuvel exclusive rights for compositions of alpha-MSH analogues and transdermal delivery systems and methods of inducing melanogenesis by topical administration.

Clinuvel's Chief Scientific Officer, Dr Hank Agersborg, said, "This has been a long time coming but our program has demonstrated the importance of melanocortins in inducing melanogenesis and thus protecting skin. This patent will allow the company a further extension of the use of afamelanotide and CUV9900 in non-invasive formulations. This patent enhances the value of our current portfolio of intellectual property in the major markets of the world."

- End -

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified three groups of patients with a clinical need for photoprotection and another group with a need for repigmentation. These patient groups range in size from 10,000 to 45 million. Clinuvel's lead compound, SCENESSE® (afamelanotide), a first-in-class drug targeting erythropoietic protoporphyria (EPP), is in Phase II and III trials in the US and Europe, and is expected to be filed before the end of 2011 for review by the European Medicines Agency. Based in Melbourne, Australia, Clinuvel has operations in Europe and the US. For further information please visit www.clinuvel.com

Investor contacts:

Australia:	Clinuvel Pharmaceuticals Limited,	T: +61 3 9660 4900
Europe:	Clinuvel AG,	T: +41 41 767 45 45
E:	investorrelations@clinuvel.com	

Media contacts:

Lachlan Hay	Nick Miles	Ted Agne
Clinuvel AG	Cabinet Privé de Conseils s.a.	The Communications Strategy Group Inc.
Baar, Switzerland	Geneva, Switzerland	Boston, Massachusetts, USA
T: +41 41 767 45 45	T: +41 22 321 4540	+1781 631 31 17
Lachlan.Hay@clinuvel.com	miles@cpc-pr.com	edagne@comstratgroup.com

Clinuvel is an Australian biopharmaceutical company focussed on developing its photoprotective drug, SCENESSE® (afamelanotide) for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:

- actual results may and often will differ materially from these forward-looking statements;
- no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for SCENESSE® can or will be achieved;
- no assurances can be given by Clinuvel that, even if its development programme for SCENESSE® is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place

Level 14 / 190 Queen Street	T +61 3 9660 4900	www.clinuvel.com
Melbourne, Victoria 3000	F +61 3 9660 4999	
Australia		